Altimmune, Inc.ALTNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank21
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P21
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-19.21%
202424.97%
2023-6.72%
2022-5.37%
202149.76%
2020180.17%
2019-3.76%
20180.29%
2017280.61%
2016-5.79%